The Impact of Ramucirumab on Survival in Patients with Advanced Solid Tumors: A Systematic Review and Meta-Analysis of Randomized II/III Controlled Trials.
作者： Kai Wang , Xiao Qu , Ying Wang , Wei Dong , Hongchang Shen
DOI: 10.1007/S40261-015-0355-X
关键词:
摘要: Ramucirumab is a fully immunoglobulin G (lgG) monoclonal antibody targeting vascular endothelial growth factor receptor type 2 (VEGFR2). Previous clinical trials suggested ramucirumab could improve the survival and increase risk of adverse effects. Here, we aimed to assess efficacy safety in treatment advanced solid tumors. Publications were searched from Pubmed, Embase database clinicaltrials.gov. Hazard ratio (HR) 95 % confidence interval (95 % CI) calculated evaluate efficacy, (RR) for Ten relevant studies included. resulted significant benefit overall [OS, HR CI 0.87 (0.82–0.93), I 2: 0.0 %] progression-free [PFS, 0.74 (0.66–0.82), 67.4 %]. Also difference time progression (TTP) objective response rate (ORR) between two groups also [0.70 (0.57–0.88) 1.78 (1.40–2.25), respectively]. total effects (TAEs, any grade) by 1 % (from 0 2 %) severe (SAEs, grade > 2) 17 % 9 26 %). The most frequently occurring TAEs fatigue (54.71 %), neutropenia (42.74 %), bleeding (37.55 %), nausea (34.63 %) stomatitis (33.74 %). Most SAEs (grade ≥3) (33.43 %), (12.08 %), leukopenia (10.59 %), hypertension (8.99 %) liver injury (8.74 %). OS PFS patients suffering SAEs.
springer.com
hku.hk
sci-hub.se 参考文章(41)
Jennifer L. Spratlin, Roger B. Cohen, Matthew Eadens, Lia Gore, D. Ross Camidge, Sami Diab, Stephen Leong, Cindy O'Bryant, Laura Q.M. Chow, Natalie J. Serkova, Neal J. Meropol, Nancy L. Lewis, E. Gabriela Chiorean, Floyd Fox, Hagop Youssoufian, Eric K. Rowinsky, S. Gail Eckhardt, Phase I Pharmacologic and Biologic Study of Ramucirumab (IMC-1121B), a Fully Human Immunoglobulin G1 Monoclonal Antibody Targeting the Vascular Endothelial Growth Factor Receptor-2 Journal of Clinical Oncology. ,vol. 28, pp. 780- 787 ,(2010) , 10.1200/JCO.2009.23.7537
Jaafar Bennouna, Javier Sastre, Dirk Arnold, Pia Österlund, Richard Greil, Eric Van Cutsem, Roger von Moos, Jose Maria Viéitez, Olivier Bouché, Christophe Borg, Claus-Christoph Steffens, Vicente Alonso-Orduña, Christoph Schlichting, Irmarie Reyes-Rivera, Belguendouz Bendahmane, Thierry André, Stefan Kubicka, Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial Lancet Oncology. ,vol. 14, pp. 29- 37 ,(2013) , 10.1016/S1470-2045(12)70477-1
Brian I. Rini, The context of blood vessels and response to VEGF-targeted therapy. Clinical Cancer Research. ,vol. 19, pp. 6647- 6649 ,(2013) , 10.1158/1078-0432.CCR-13-2479
Lalita Yadav, Naveen Puri, Varun Rastogi, Pranali Satpute, Vandana Sharma, Tumour Angiogenesis and Angiogenic Inhibitors: A Review JOURNAL OF CLINICAL AND DIAGNOSTIC RESEARCH. ,vol. 9, ,(2015) , 10.7860/JCDR/2015/12016.6135
Denise A. Yardley, Paul D. Richards, James Andrew Reeves, Elizabeth Claire Dees, Cynthia R. C. Osborne, Hatem Hussein Soliman, Devchand Paul, Foluso Olabisi Ademuyiwa, Troy H. Guthrie, Jane L. Bromund, Yihuan Xu, Ayman B. Ibrahim, Final results of a phase 2 study of ramucirumab (RAM) plus eribulin (E) versus E in advanced metastatic breast cancer (MBC). Journal of Clinical Oncology. ,vol. 32, pp. 1035- 1035 ,(2014) , 10.1200/JCO.2014.32.15_SUPPL.1035
Harry H. Yoon, Johanna C. Bendell, Fadi S. Braiteh, Irfan Firdaus, Philip Agop Philip, Allen Lee Cohn, Nancy Lewis, Daniel M. Anderson, Edward Arrowsmith, Jonathan D. Schwartz, Yihuan Xu, Minori Koshiji, Steven R. Alberts, Zev A. Wainberg, Ramucirumab (RAM) plus FOLFOX as front-line therapy (Rx) for advanced gastric or esophageal adenocarcinoma (GE-AC): Randomized, double-blind, multicenter phase 2 trial. Journal of Clinical Oncology. ,vol. 32, pp. 4004- 4004 ,(2014) , 10.1200/JCO.2014.32.15_SUPPL.4004
Lindsey A. Torre, Freddie Bray, Rebecca L. Siegel, Jacques Ferlay, Joannie Lortet-Tieulent, Ahmedin Jemal, Global cancer statistics, 2012 CA: A Cancer Journal for Clinicians. ,vol. 65, pp. 87- 108 ,(2015) , 10.3322/CAAC.21262
Diane R. Bielenberg, Bruce R. Zetter, The Contribution of Angiogenesis to the Process of Metastasis The Cancer Journal. ,vol. 21, pp. 267- 273 ,(2015) , 10.1097/PPO.0000000000000138
Robert C. Doebele, David Spigel, Mustapha Tehfe, Sachdev Thomas, Martin Reck, Sunil Verma, Janice Eakle, Frederique Bustin, Jerome Goldschmidt, Dachuang Cao, Ekaterine Alexandris, Sergey Yurasov, D. Ross Camidge, Philip Bonomi, Phase 2, randomized, open-label study of ramucirumab in combination with first-line pemetrexed and platinum chemotherapy in patients with nonsquamous, advanced/metastatic non-small cell lung cancer Cancer. ,vol. 121, pp. 883- 892 ,(2015) , 10.1002/CNCR.29132
Zexing Wang, Jun Zhang, Liang Zhang, Pengying Liu, Yamin Xie, Qin Zhou, Risk of gastrointestinal perforation in cancer patients receiving ramucirumab: a meta-analysis of randomized controlled trials Journal of Chemotherapy. ,vol. 28, pp. 328- 334 ,(2016) , 10.1179/1973947815Y.0000000053